Celgene stock: buy or sell?
November 20th, 2019
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide.
Should I buy Celgene stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Celgene stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Celgene stock a buy?
Financial institutions and banks post stock ratings everyday.Unfortunately, we couldn't detect any rating for CELG stock for the last month.
Celgene stock analysis
Celgene remained constant a neutral 0.10% and closed at $108.24.
Celgene shares remained stable 0.10% to $108.24 on November. From a daily perspective, CELG is in a short term uptrend after plotting its last bottom ($107.21, on November) higher than the previous bottom, and its last top ($110.70, on November) also over the previous top. Now trading in between its last bottom and last top CELG might consolidate in a plain range, waiting to break out over $110.70 or down under $107.21. Since SMA50d and SMA100d crossed up on September, CELG price climbed $8.82 per share (8.87%). On August CELG price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock.
After climbing for 4 weeks, by mid November 2019 Celgene decreased an unpleasant -1.62%, closing at $108.24.
Celgene stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, CELG might consolidate in a flat-base, waiting to break out over or down under . By mid April 2019, SMA20w and SMA40w crossed up triggering a rise of 14.98%. Since price and SMA40w lines crossed up late December 2018, CELG climbed $45.81 (73.38%).
Celgene stock price history
Celgene stock went public on July 28th, 1987 with a price of $0.001. Since then, CELG stock grew a inf%, with an average of inf% per year. If you had invested $1,000 in Celgene stock in 1987, it would worth $inf today.
1: Adjusted price after possible price splits or reverse-splits.
Celgene stock historical price chart
CELG stock reached 52-week highs on November at $110.70, and all-time highs 2017-10-02 with a price of 147.17.
Celgene stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we have not found any price forecast for Celgene stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareSince last May, when Celgene presented its last earnings report, it . As soon as we get its actual EPS from the earnings report, we will update this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw an astounding gain of 17.52% to $15,281.00 million dollars. Instead, its earnings margin (compared to revenues) inched to 26.48%, that is $4,046.00 million. Celgene fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Celgene TTM sales up to March 2019 were $15,768.00 and earnings $4,745.00 million dollars. If we compare this TTM figures with the last reported annuality, we can review Celgene business evolution since December 2018: Annual sales up to March, compared to lastest yearly report, raised a beatiful 3.19%. In line, profit margin (net income/revenues) gained at 26.48%.
|2013||$6,480 M||-||$1,450 M22.4%||-|
|2014||$7,670 M||18.37%||$2,000 M26.1%||37.92%|
|2015||$9,256 M||20.67%||$1,602 M17.3%||-19.90%|
|2016||$11,229 M||21.32%||$1,999 M17.8%||24.79%|
|2017||$13,003 M||15.80%||$2,940 M22.6%||47.06%|
|2018||$15,281 M||17.52%||$4,046 M26.5%||37.62%|
|TTM||$15,768 M||3.19%||$4,745 M30.1%||17.28%|
Quarterly financial resultsCelgene reported $4,025.00 M in revenues for 2019-Q1, a -0.30% decline compared to previous quarter. Reported quarter income marked $1,545.00 M with a profit margin of 38.39%. Profit margin boosted a 11.81% compared to previous quarter when profit margin was 26.58%. When comparing sales to same quarter last year, Celgene sales marked an amazing growth and rocketed a 13.76%.
|2017-Q2||$3,190 M||-||$1,060 M33.2%||-|
|2017-Q3||$3,280 M||2.82%||$988 M30.1%||-6.79%|
|2017-Q4||$3,483 M||6.19%||$-81 M-2.3%||-108.20%|
|2018-Q1||$3,538 M||1.58%||$846 M23.9%||-1,144.44%|
|2018-Q2||$3,814 M||7.80%||$1,045 M27.4%||23.52%|
|2018-Q3||$3,892 M||2.05%||$1,082 M27.8%||3.54%|
|2018-Q4||$4,037 M||3.73%||$1,073 M26.6%||-0.83%|
|2019-Q1||$4,025 M||-0.30%||$1,545 M38.4%||43.99%|
Celgene ownershipWhen you are planning to invest in shares of a stock, it's worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Celgene, 0.22% of all outstanding shares are owned by its staff.
In case of Celgene stock, 77.62% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CELG stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$77.0 B|
|Total shares||711.7 M|
|Float shares||709.4 M|
|- Institutional holdings (%)||77.6%|
|- Insider holdings (%)||0.2%|
|Shares in short selling||0.0%|
|Wednesday, November 20th, 2019|
|Day range||$107.27 - $108.59|
|Average true range||$1.06|
|50d mov avg||$103.23|
|100d mov avg||$98.65|
|200d mov avg||$95.60|
Celgene performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Celgene performance to :
Celgene competitorsUnfortunately, we could not find any public company that could be defined as Celgene competitor. This doesn't mean Celgene does not have any competitor in the market, it's just we could not detected it.
Latest Celgene stock news
- InvestorPlaceNasdaq Today: Celgene, Ulta, Caesars’ BuyoutJune 24, 2019
- Seeking AlphaBristol-Myers Squibb And Celgene - On The Path To A Valuable CombinationJune 20, 2019
- Seeking AlphaCelgene's Long Journey Through Regulatory Filings For Ozanimod Might Finally Pay OffJune 12, 2019
- InvestorPlace3 Big Stock Charts for Monday: American Airlines Group, Mylan and CelgeneMay 6, 2019
- Seeking AlphaCelgene And Acceleron: BLA Luspatercept Has Strong PotentialApril 11, 2019